METHOD AND KIT FOR DETERMINING OF HORMONE THERAPY SENSITIVITY IN PROSTATE CANCER PATIENT

• Main Authors: WATANABE SHINYA, KOJIMA YOSHITAKA, HOSHI SEIJI, TOGASHI REIKO, IMAI JUNICHI
• Format: Patent
• Language: English; Japanese
• Published: 03.04.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

To provide a method for identifying a biomarker (gene set) in order to detect a case in which hormone therapy is effective in a prostate cancer patient, and a method for detecting a case in which hormone therapy is effective by using the biomarker.SOLUTION: A method for determining sensitivity of hormone therapy for prostate cancer includes a process of measuring an expression level of at least one kind of gene in the group consisting of FHL1 gene, LTBP4 gene, PLAGL1 gene, AXIN2 gene, ATP2C2 gene, TNFRSF19 gene, ITGA8 gene, F13A1 gene, SIX1 gene, HS3ST1 gene, APOE gene, POLB gene, PYCR1 gene, F5 gene, AMIGO2 gene, FABP5 gene, CNN1 gene, TNS1 gene, PDE5A gene, C9orf152 gene, AFF3 gene, HSD17B4 gene, DEGS1 gene, PRR16 gene, MYH11 gene, ZWINT gene, HMGB2 gene and MK167 gene in a sample to be tested derived from a subject.SELECTED DRAWING: None 【課題】 前立腺癌患者において、ホルモン治療が有効な症例を検出するためのバイオマーカー（遺伝子セット）の同定、および、当該バイオマーカーを用いてホルモン治療が有効な症例を検出する方法を提供することを課題とする。【解決手段】前立腺癌のホルモン治療に対する感受性を判別する方法であって、被験者由来の被検試料におけるFHL1遺伝子、LTBP4遺伝子、PLAGL1遺伝子、AXIN2遺伝子、ATP2C2遺伝子、TNFRSF19遺伝子、ITGA8遺伝子、F13A1遺伝子、SIX１遺伝子、HS3ST1遺伝子、APOE遺伝子、POLB遺伝子、PYCR1遺伝子、F5遺伝子、AMIGO2遺伝子、FABP5遺伝子、CNN1遺伝子、TNS1遺伝子、PDE5A遺伝子、C9orf152遺伝子、AFF3遺伝子、HSD17B4遺伝子、DEGS1遺伝子、PRR16遺伝子、MYH11遺伝子、ZWINT遺伝子、HMGB2遺伝子およびMK167遺伝子からなる群における少なくとも１つの遺伝子の発現レベルを測定する工程を含む、判別方法。【選択図】なし